Graphite Bio, Inc. (NASDAQ:GRPH – Free Report) – Research analysts at Leerink Partnrs decreased their Q4 2023 EPS estimates for Graphite Bio in a research report issued on Monday, November 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.16) per share for the quarter, down from their previous estimate of ($0.09). The consensus estimate for Graphite Bio’s current full-year earnings is ($1.67) per share.
Graphite Bio Stock Performance
Shares of Graphite Bio stock opened at $2.26 on Thursday. The stock has a market capitalization of $130.74 million, a price-to-earnings ratio of -0.98 and a beta of -0.05. Graphite Bio has a 1-year low of $1.59 and a 1-year high of $3.69. The firm’s 50-day moving average price is $2.37 and its two-hundred day moving average price is $2.59.
Hedge Funds Weigh In On Graphite Bio
A number of large investors have recently modified their holdings of GRPH. SG Americas Securities LLC acquired a new position in shares of Graphite Bio during the third quarter worth approximately $31,000. Dimensional Fund Advisors LP acquired a new position in shares of Graphite Bio during the third quarter worth approximately $34,000. American International Group Inc. acquired a new position in shares of Graphite Bio during the second quarter worth approximately $35,000. Squarepoint Ops LLC acquired a new position in shares of Graphite Bio during the first quarter worth approximately $35,000. Finally, Wells Fargo & Company MN lifted its position in shares of Graphite Bio by 312.3% during the second quarter. Wells Fargo & Company MN now owns 13,838 shares of the company’s stock worth $36,000 after purchasing an additional 10,482 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.
About Graphite Bio
Graphite Bio, Inc, a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
- Five stocks we like better than Graphite Bio
- Investing in the High PE Growth Stocks
- Amazon, Target, Walmart in a race for fastest delivery
- Mega Cap Stocks: What They Are and How to Invest
- Palo Alto Networks: the one security stock to rule them all
- How to Calculate Options Profits
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Graphite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graphite Bio and related companies with MarketBeat.com's FREE daily email newsletter.